Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.
Non-small Cell Lung Cancer
DRUG: Anlotinib plus the same Immune Checkpoint Inhibitors.|DRUG: Anlotinib plus the new Immune Checkpoint Inhibitors.|DRUG: Anlotinib
Progression free survival time (PFS), Progression free survival time define as first dose to first documented disease progression assessed by investigator or death due to any cause., Time from first subject dose to study completion, or up to 36 month.
Objective Response Rate (ORR), Objective response rate define as the proportion of subjects who have a complete response (CR) or a partial response (PR)., Time from first subject dose to study completion, or up to 36 month.|Overall survival (OS), To assess overall survival, define as first dose to the death of the subject due to any cause., Time from first subject dose to study completion, or up to 36 month.
This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC. The primary endpoint was PFS.